Q3 2019 Earnings Call

Yep in patients with CLL or Mcl at the American Society of Hematology or Ash annual meeting in December .

We also plan to present interim data from our ongoing phase one clinical trial of Teekay to 16 in patients with Ewing's sarcoma at the connective tissue oncology society or seed costs annual meeting later this month.

We also anticipate selecting a candidate car T construct for treating patients with hematologic cancers expressing RAR one in the first half of 2020.

With that I'd like to turn it over to our Chief Medical Officer, Frank Shoe for a more detailed review of our pipeline.

Thank you Jim.

We've made solid progress during a short time since I joined nocturnal in August I'd like to complement this team for their hard work and commitment and for the cooperation I've witnessed since joining the company Im very excited about the company's pipeline opportunities and im going to spend the next few minutes, taking you through a more in depth look at or product candidates.

Our lead clinical program.

His CIRM tomorrow, it's a monoclonal antibody designed to inhibit the ROI or one pathway.